BioSight
Back
Ascendis Pharma A/S logo

ASND

NASDAQHELLERUP
Ascendis Pharma A/S
$229.38-6.52%1Y
ASND · daily close · illustrative · 0 catalysts marked
1Y high$245.381Y low$220.28range$25.10(11%)past catalysts

Pipeline10

Chemotherapy drug
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer

Generic 'chemotherapy' label without a specific agent identified. Indicates a cytotoxic regimen used as comparator or backbone.

small-molecule
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Phase 2Achondroplasia
small-molecule
Lonapegsomatropin
Phase 2Turner Syndrome

SKYTROFA is a pegylated human growth hormone (somatropin) for once-weekly subcutaneous injection [see Clinical Pharmacology (12.3) ] .

small-molecule
Navepegritide
Phase 2Achondroplasia

CNP released from navepegritide has the same receptor binding affinity and activity as endogenous CNP. CNP binds to natriuretic peptide receptor-B (NPR-B), which inhibits the mitogen activated protein kinase signaling (MAPK) pathway.

small-molecule
Pembrolizumab
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer

Anti-PD-1 monoclonal antibody (Keytruda) that blocks the PD-1 checkpoint, restoring anti-tumor immune response. FDA-approved across many cancers including NSCLC, melanoma, and gastroesophageal cancer.

monoclonal-antibody
PD-1 antagonist
→ PD-1
Somatropin
Phase 2Turner Syndrome

Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells.

small-molecule
TransCon IL-2 β/γ
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer

Sustained-release IL-2 receptor βγ-selective agonist (Ascendis Pharma) designed to expand effector T cells while avoiding regulatory T-cell expansion. Phase 1/2 in solid tumors.

peptide
IL-2 βγ-selective receptor agonist
→ IL-2 βγ receptor (CD122/CD132, sparing CD25)
TransCon TLR7/8 Agonist
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer

Sustained-release TLR7/TLR8 agonist (Ascendis Pharma) using TransCon prodrug technology for intratumoral delivery. Phase 1/2 in solid tumors as immunotherapy combination.

peptide
TLR7/8 agonist (intratumoral immune activator)
→ TLR7 / TLR8
Trastuzumab
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer

Anti-HER2 monoclonal antibody (Herceptin) that binds the extracellular domain of HER2, blocking signaling and triggering ADCC. Standard of care in HER2-positive breast and gastric cancers.

monoclonal-antibody
HER2 antagonist
→ HER2
Trastuzumab emtansine (T-DM1)
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer

Anti-HER2 antibody conjugated to DM1 (a maytansine microtubule inhibitor). Approved as Kadcyla in HER2-positive breast cancer adjuvant and metastatic settings.

antibody-drug-conjugate
HER2-directed antibody-drug conjugate
→ HER2 (DM1 payload)

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.